Cohort Data
Our prospective research cohort is advancing understanding of rheumatic immune-related adverse events.
The CanRIO prospective cohort study tracks patients experiencing rheumatic immune-related adverse events (irAEs) from immune checkpoint inhibitor therapy across Canada. This longitudinal database provides valuable insights into the presentation, treatment, and long-term outcomes of these conditions.
Cohort at a Glance
PLACEHOLDER: Confirm exact stats with Megan/Faiza
Research Focus Areas
Clinical Presentations
Understanding the spectrum of rheumatic irAEs and their clinical characteristics.
Treatment Outcomes
Evaluating the effectiveness of different treatment approaches.
Long-term Follow-up
Tracking outcomes after immunotherapy completion.
Risk Factors
Identifying predictors of rheumatic irAE development.
Key Findings
Research from the CanRIO cohort has contributed to understanding:
- The chronicity of inflammatory arthritis after immunotherapy discontinuation
- Safety of checkpoint inhibitor rechallenge in patients with prior irAEs
- The impact of pre-existing autoimmune disease on irAE development
- Effective treatment strategies for persistent symptoms
View our publications page for the latest research findings.
Participating Sites
The CanRIO cohort includes data from academic centres across Canada: